Diligence memo · auto-generated · as of July 2, 2026
ViaCyte Inc.
ViaCyte Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
ViaCyte Inc. operates in Biotechnology, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ViaCyte Inc. has raised $150M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $54M on 2021-04-06.
Most recent recorded round closed around 2021-04-06.
Valuation (modeled)modeled
Provath models ViaCyte Inc. at approximately $1.7B (range $167M–$3.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.85× the median modeled value of Series C Biotechnology companies in 2019–2021 (120 peers) — value vs value, same stage and era. Within the normal band (85% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 23 months.
Last raise 5.2 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Biotechnology peers (4293 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Stem Biotech LLC, Kinnate Biopharma Inc., Arcutis Biotherapeutics, Inc., DNA Research INST LLC, M3 Biotechnology, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.